IMPACT OF IMMUNOTHERAPY ARRIVAL IN CHEMOTHERAPY PRODUCTION UNITS: RETROSPECTIVE STUDY AND PROJECTION WITH ANTI-PD-1 AGENTS

T. Catalot, A. Guedon, W. Farhat, A. Savry, L. Gauthier-Villano, B. Pourroy, P. Bertault-Peres
Oncopharma, Hôpital de La Timone, 264 Rue Saint-Pierre, 13385 Marseille, France

Objective:
• To evaluate retrospectively Immunotherapy (IT) arrival impact in dermatology
• To grasp IT arrival impact in bladder and head and neck (HN) cancer

Material and Methods:
• Real-life datas are extracted from our prescription software Chimio®.
• Production flow in melanoma: retrospective assessment on 1 year compared to an assessment conducted before IT arrival
• Production flow in bladder and HN cancers: prospective study on 1 year
  o we inventoried preparations used in second line in metastatic cancers
  o we predicted IT production for nivolumab and pembrolizumab according to their administration schemes

Results:

Global production in function of oncology specialties (40 000 preparations a year)

Anticancer-drug Production in Dermatology before and after IT arrival

Projection of production with IT arrival in HN cancers

Projection of production with IT arrival in bladder cancers

Conclusion
Global production increased with IT arrival in dermatology. The production frequencies decrease with IT but the survival time increases. It may explained this rise.

Global production decreases in HN and bladder cancers, according to our prediction. But it doesn’t take into account survival time improvement due to IT. Considering dermatology experience, we can suppose that survival time in HN and bladder cancers will increase and global production will grow consequently. It may represent around 3000 additional preparations per year (+ 7,5 %).

Further studies (including atezolizumab or other IT in lung and renal cancers) need to be conducted to assess this impact on a global production in a chemotherapy production units.